108 related articles for article (PubMed ID: 22042473)
1. Hedgehog inhibition with the orally bioavailable Smo antagonist LDE225 represses tumor growth and prolongs survival in a transgenic mouse model of islet cell neoplasms.
Fendrich V; Wiese D; Waldmann J; Lauth M; Heverhagen AE; Rehm J; Bartsch DK
Ann Surg; 2011 Nov; 254(5):818-23; discussion 823. PubMed ID: 22042473
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of heat shock protein 90 with AUY922 represses tumor growth in a transgenic mouse model of islet cell neoplasms.
Fendrich V; Wichmann S; Wiese D; Waldmann J; Lauth M; Rexin P; L-Lopez C; Schlitt HJ; Bartsch DK; Lang SA
Neuroendocrinology; 2014; 100(4):300-9. PubMed ID: 25301256
[TBL] [Abstract][Full Text] [Related]
3. Hedgehog inhibition with cyclopamine represses tumor growth and prolongs survival in a transgenic mouse model of islet cell tumors.
Fendrich V; Rehm J; Waldmann J; Buchholz M; Christofori G; Lauth M; Slater EP; Bartsch DK
Ann Surg; 2011 Mar; 253(3):546-52. PubMed ID: 21239987
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells.
D'Amato C; Rosa R; Marciano R; D'Amato V; Formisano L; Nappi L; Raimondo L; Di Mauro C; Servetto A; Fulciniti F; Cipolletta A; Bianco C; Ciardiello F; Veneziani BM; De Placido S; Bianco R
Br J Cancer; 2014 Sep; 111(6):1168-79. PubMed ID: 25093491
[TBL] [Abstract][Full Text] [Related]
5. Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor.
Skvara H; Kalthoff F; Meingassner JG; Wolff-Winiski B; Aschauer H; Kelleher JF; Wu X; Pan S; Mickel L; Schuster C; Stary G; Jalili A; David OJ; Emotte C; Antunes AM; Rose K; Decker J; Carlson I; Gardner H; Stuetz A; Bertolino AP; Stingl G; De Rie MA
J Invest Dermatol; 2011 Aug; 131(8):1735-44. PubMed ID: 21430703
[TBL] [Abstract][Full Text] [Related]
6. NVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivo.
Jalili A; Mertz KD; Romanov J; Wagner C; Kalthoff F; Stuetz A; Pathria G; Gschaider M; Stingl G; Wagner SN
PLoS One; 2013; 8(7):e69064. PubMed ID: 23935925
[TBL] [Abstract][Full Text] [Related]
7. Smoothened antagonists reverse taxane resistance in ovarian cancer.
Steg AD; Katre AA; Bevis KS; Ziebarth A; Dobbin ZC; Shah MM; Alvarez RD; Landen CN
Mol Cancer Ther; 2012 Jul; 11(7):1587-97. PubMed ID: 22553355
[TBL] [Abstract][Full Text] [Related]
8. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer.
Feldmann G; Fendrich V; McGovern K; Bedja D; Bisht S; Alvarez H; Koorstra JB; Habbe N; Karikari C; Mullendore M; Gabrielson KL; Sharma R; Matsui W; Maitra A
Mol Cancer Ther; 2008 Sep; 7(9):2725-35. PubMed ID: 18790753
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the hedgehog pathway targets the tumor-associated stroma in pancreatic cancer.
Hwang RF; Moore TT; Hattersley MM; Scarpitti M; Yang B; Devereaux E; Ramachandran V; Arumugam T; Ji B; Logsdon CD; Brown JL; Godin R
Mol Cancer Res; 2012 Sep; 10(9):1147-57. PubMed ID: 22859707
[TBL] [Abstract][Full Text] [Related]
10. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.
Rodon J; Tawbi HA; Thomas AL; Stoller RG; Turtschi CP; Baselga J; Sarantopoulos J; Mahalingam D; Shou Y; Moles MA; Yang L; Granvil C; Hurh E; Rose KL; Amakye DD; Dummer R; Mita AC
Clin Cancer Res; 2014 Apr; 20(7):1900-9. PubMed ID: 24523439
[TBL] [Abstract][Full Text] [Related]
11. A novel synthetic smoothened antagonist transiently inhibits pancreatic adenocarcinoma xenografts in a mouse model.
Strand MF; Wilson SR; Dembinski JL; Holsworth DD; Khvat A; Okun I; Petersen D; Krauss S
PLoS One; 2011; 6(6):e19904. PubMed ID: 21698280
[TBL] [Abstract][Full Text] [Related]
12. TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.
Ibuki N; Ghaffari M; Pandey M; Iu I; Fazli L; Kashiwagi M; Tojo H; Nakanishi O; Gleave ME; Cox ME
Int J Cancer; 2013 Oct; 133(8):1955-66. PubMed ID: 23564295
[TBL] [Abstract][Full Text] [Related]
13. Tumor-stroma interaction in orthotopic primary pancreatic cancer xenografts during hedgehog pathway inhibition.
Chang Q; Foltz WD; Chaudary N; Hill RP; Hedley DW
Int J Cancer; 2013 Jul; 133(1):225-34. PubMed ID: 23280784
[TBL] [Abstract][Full Text] [Related]
14. Design of 1-piperazinyl-4-arylphthalazines as potent Smoothened antagonists.
Lucas BS; Aaron W; An S; Austin RJ; Brown M; Chan H; Chong A; Hungate R; Huang T; Jiang B; Johnson MG; Kaizerman JA; Lee G; McMinn DL; Orf J; Powers JP; Rong M; Toteva MM; Uyeda C; Wickramasinghe D; Xu G; Ye Q; Zhong W
Bioorg Med Chem Lett; 2010 Jun; 20(12):3618-22. PubMed ID: 20493695
[TBL] [Abstract][Full Text] [Related]
15. The hedgehog pathway and pancreatic cancer.
Hidalgo M; Maitra A
N Engl J Med; 2009 Nov; 361(21):2094-6. PubMed ID: 19923581
[No Abstract] [Full Text] [Related]
16. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer.
Feldmann G; Habbe N; Dhara S; Bisht S; Alvarez H; Fendrich V; Beaty R; Mullendore M; Karikari C; Bardeesy N; Ouellette MM; Yu W; Maitra A
Gut; 2008 Oct; 57(10):1420-30. PubMed ID: 18515410
[TBL] [Abstract][Full Text] [Related]
17. Blockade of the hedgehog pathway inhibits osteophyte formation in arthritis.
Ruiz-Heiland G; Horn A; Zerr P; Hofstetter W; Baum W; Stock M; Distler JH; Nimmerjahn F; Schett G; Zwerina J
Ann Rheum Dis; 2012 Mar; 71(3):400-7. PubMed ID: 22233602
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease.
Zerr P; Palumbo-Zerr K; Distler A; Tomcik M; Vollath S; Munoz LE; Beyer C; Dees C; Egberts F; Tinazzi I; Del Galdo F; Distler O; Schett G; Spriewald BM; Distler JH
Blood; 2012 Oct; 120(14):2909-17. PubMed ID: 22915638
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of smoothened activates the sonic hedgehog signaling pathway in pancreatic cancer-associated fibroblasts.
Walter K; Omura N; Hong SM; Griffith M; Vincent A; Borges M; Goggins M
Clin Cancer Res; 2010 Mar; 16(6):1781-9. PubMed ID: 20215540
[TBL] [Abstract][Full Text] [Related]
20. Tumor Priming by SMO Inhibition Enhances Antibody Delivery and Efficacy in a Pancreatic Ductal Adenocarcinoma Model.
Wang J; Chan DKW; Sen A; Ma WW; Straubinger RM
Mol Cancer Ther; 2019 Nov; 18(11):2074-2084. PubMed ID: 31363010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
